Eldelumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Eldelumab
Accession Number
DB06116
Type
Small Molecule
Groups
Investigational
Description

MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory bowel disease and multiple sclerosis.

Synonyms
Not Available
External IDs
BMS-936557 / MDX-1100
Categories
UNII
15O91A27I5
CAS number
946414-98-8
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Investigated for use/treatment in ulcerative colitis.

Pharmacodynamics
Not Available
Mechanism of action

MDX-1100 binds selectively to CXCL10 and blocks CXCL10 induced calcium flux and cell migration.

TargetActionsOrganism
UC-X-C motif chemokine 10Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Eldelumab.
AbituzumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Eldelumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Eldelumab.
AducanumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Eldelumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Eldelumab.
AlirocumabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Alirocumab.
AmatuximabThe risk or severity of adverse effects can be increased when Eldelumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Eldelumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Eldelumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentUlcerative Colitis (UC)1
2CompletedTreatmentCrohn's Disease (CD)1
2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentUlcerative Colitis (UC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Receptor binding
Specific Function
Chemotactic for monocytes and T-lymphocytes. Binds to CXCR3.
Gene Name
CXCL10
Uniprot ID
P02778
Uniprot Name
C-X-C motif chemokine 10
Molecular Weight
10880.915 Da

Drug created on November 18, 2007 11:30 / Updated on November 02, 2018 06:13